Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by HC Wainwright
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $46.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 47.44% from the company’s previous close. […]
More Stories
Top DevOps Testing Tools for Faster Software Delivery in 2026
Most teams don’t have a testing problem. They have a speed problem. DevOps Testing Tools promise faster feedback loops, but...
Long Story Short Season 2 Is Renewed! Release Date, Plot, and More
Netflix has recently given anime fans a major reason to celebrate by renewing Long Story Short for a new season....
MGA, Curaçao, and German Licences: What the Differences Mean for Users
Choosing an online casino often comes down to one detail most players skim past: the licence badge in the footer....
Is I Will Find You Season 2 Returning? Renewal Status, Cast, and Plot
In 2026, the first season of the popular and most awaited series was released. I Will Find You first dropped...
Top Ahrefs SEO Tools to Boost a Website’s Traffic and Sales
Website analysis has become one of the most useful SEO tools used by several companies nowadays. Ahrefs SEO tool provides...
Planning Group Travel That Doesn’t Fall Apart at the Logistics Stage
Anyone who has organized transportation for a wedding party, a school trip, or a corporate retreat knows the pattern. The...